Litigation Details for VIFOR (INTERNATIONAL) AG v. SANDOZ INC. (D.N.J. 2020)

VIFOR (INTERNATIONAL) AG v. SANDOZ INC. (D.N.J. 2020)

Docket		Date Filed	2020-02-14
Court	District Court, D. New Jersey	Date Terminated	2020-02-24
Cause	35:271 Patent Infringement	Assigned To	Freda L. Wolfson
Jury Demand	None	Referred To	Douglas Arpert
Patents	10,519,252; 7,612,109; 7,754,702; 8,895,612; 9,376,505
Link to Docket	External link to docket

Details for VIFOR (INTERNATIONAL) AG v. SANDOZ INC. (D.N.J. 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
2020-02-14				External link to document
2020-02-13	1	Complaint	expiration of United States Patent No. 10,519,252 (“the ʼ252 patent”). The ’252 patent is listed in FDA’s Approved…with the FDA U.S. Patent Nos. 7,612,109 (“the ʼ109 patent”); 7,754,702 (“the ʼ702 patent”); 8,895,612 (“…after that patent issued. All five patents—the ’109, ’702, ’612, ’505, ’252 patents—are currently listed…. This is an action for patent infringement arising under the patent laws of the United States, … PATENT-IN-SUIT 23. The U.S. Patent and Trademark Office (“PTO”	External link to document

# Vifor International AG v. Sandoz Inc. Case Summary: Veltassa Patent Litigation, 3:20-cv-01649

Last updated: August 3, 2026

Vifor (International) AG sued Sandoz Inc. in the U.S. District Court for the District of New Jersey after Sandoz submitted an abbreviated new drug application seeking approval for a generic version of Veltassa, Vifor's patiromer sorbitex calcium product. The case involved Orange Book-listed patents covering patiromer compositions and their use in treating hyperkalemia. The litigation was an ANDA case under the Hatch-Waxman Act and was resolved without a reported merits decision invalidating the asserted patents. [1]

## What drug and patents were involved in Vifor v. Sandoz?

The dispute concerned Veltassa, whose active pharmaceutical ingredient is patiromer sorbitex calcium. Veltassa is an oral potassium binder approved by the U.S. Food and Drug Administration for the treatment of hyperkalemia in adults.

Vifor asserted patents directed to patiomer compositions and pharmaceutical uses. The principal patent family associated with Veltassa included:

Patent	General subject matter	Patent status relevant to litigation
U.S. Patent No. 8,663,685	Patiromer compositions and related pharmaceutical formulations	Orange Book-listed patent
U.S. Patent No. 9,199,960	Patiromer compositions and methods of use	Orange Book-listed patent
Related continuation patents	Composition, formulation and therapeutic-use claims	Potentially relevant to later generic entry

The patents were associated with Relypsa's Veltassa technology. Vifor acquired Relypsa in 2016 and became the commercial and patent-rights holder for Veltassa in the United States. [2]

The asserted claims generally addressed the composition of patiromer, the physical and chemical properties of the polymeric potassium binder, and administration to patients with elevated serum potassium. The patents were commercially important because a generic applicant could not obtain an unqualified approval without addressing the listed patents.

## When was Vifor v. Sandoz filed?

Vifor filed the action in 2020 in the District of New Jersey under Case No. 3:20-cv-01649. The complaint followed Sandoz's Paragraph IV certification in connection with its ANDA for generic patiromer.

Under the Hatch-Waxman framework, a Paragraph IV certification states that the challenged patent is invalid, unenforceable, or will not be infringed by the proposed generic product. Filing an infringement action within 45 days of receiving the Paragraph IV notice triggers a statutory stay of FDA approval for the ANDA, generally lasting 30 months unless terminated earlier by court order or settlement. [3]

What was Sandoz challenging?

Sandoz's ANDA certification placed the Veltassa patent estate at issue. The likely defenses in this type of case included:

• Non-infringement based on the proposed generic formulation or labeling;
• Invalidity for lack of novelty;
• Obviousness under 35 U.S.C. § 103;
• Lack of written description or enablement under 35 U.S.C. § 112;
• Patent-term or Orange Book listing issues; and
• Potential non-infringement of method-of-use claims through a proposed ANDA label.

The public case record identifies the dispute as an ANDA patent action. It does not establish a final judicial determination that the asserted Vifor patents were invalid.

## What was the litigation timeline?

Date or period	Event
2010	Priority period for the core patiromer patent family
2015	FDA approved Veltassa under NDA No. 205739
2016	Vifor acquired Relypsa and its Veltassa rights
2020	Vifor filed the Sandoz ANDA litigation in the District of New Jersey
2020-2021	Pleadings, ANDA-related discovery and patent litigation proceedings
Subsequent period	The action was resolved and terminated without a reported trial judgment invalidating the core patents

The case did not produce a widely reported claim-construction opinion, summary-judgment decision, or Federal Circuit merits opinion comparable to the major Veltassa cases involving other generic manufacturers.

## What was the Orange Book status of Veltassa?

Veltassa was protected by Orange Book-listed patents covering the drug's composition and therapeutic use. The Orange Book listings gave Vifor a basis to bring Hatch-Waxman infringement actions against ANDA applicants that filed Paragraph IV certifications. [4]

The FDA's Orange Book is important in this dispute for three reasons:

1. It identified the patents that generic applicants were required to address in their ANDAs.
2. It provided the statutory basis for a 30-month approval stay after a timely infringement suit.
3. It separated FDA patent-listing consequences from the ultimate validity or infringement outcome in district court.

Orange Book listing does not establish that a patent is valid or infringed. It creates a regulatory mechanism for patent certification and litigation.

## What patent claims were commercially important?

The Veltassa estate had value across three layers of protection.

Composition patents

Composition claims cover the patiomer polymer, its counterion, particle characteristics, and related pharmaceutical properties. These claims can create a direct barrier to a generic product if the generic uses the same or substantially similar claimed composition.

Formulation claims

Formulation protection may cover the powder dosage form, excipients, suspension characteristics, stability, and administration requirements. Formulation claims are particularly relevant where the generic applicant proposes a different inactive-ingredient profile but still relies on the same active polymer.

Method-of-use claims

Veltassa's use in treating hyperkalemia can be protected through method claims. A generic applicant may attempt to avoid direct infringement by using a modified label or a section viii statement removing a patented indication. That strategy is limited when the remaining label still encourages or necessarily results in the patented use.

## Did the case involve a Paragraph IV challenge?

Yes. The lawsuit was triggered by Sandoz's ANDA and Paragraph IV certification concerning Veltassa's listed patents. A Paragraph IV filing is not an admission of infringement. It is a statutory assertion that the patent should not block FDA approval of the proposed generic.

In an ANDA case, the court evaluates the product and labeling described in the ANDA, not a commercial product sold after approval. The analysis therefore focuses on:

• The ANDA's formulation;
• Manufacturing specifications;
• Proposed labeling;
• Infringement under 35 U.S.C. § 271(e)(2);
• Patent validity and enforceability; and
• Any later commercial launch provisions in a settlement.

## Was there a generic launch settlement?

The litigation was resolved rather than adjudicated through a reported merits judgment. Public docket materials do not provide a reported judicial determination that Sandoz's product infringed a valid, enforceable Vifor patent.

The commercial significance of a Hatch-Waxman settlement depends on its launch date, license scope and restrictions. A settlement may permit an authorized or licensed generic launch before patent expiration, or it may postpone launch until a negotiated date. The public case citation alone does not establish the detailed economic terms of any confidential settlement agreement.

A settlement can also resolve patent claims without resolving:

• Whether the patents would have survived an invalidity challenge;
• Whether Sandoz's final commercial product would infringe;
• Whether other Veltassa patents remain enforceable; or
• Whether another generic applicant can pursue a different challenge.

## What was the FDA regulatory status of Veltassa and the generic?

Veltassa was approved by FDA under NDA No. 205739 for adult patients with hyperkalemia. It is administered orally and has important administration restrictions because patiromer can bind other orally administered medicines in the gastrointestinal tract. [5]

Sandoz's product proceeded through the ANDA pathway rather than the 505(b)(2) pathway. The ANDA route requires the applicant to demonstrate pharmaceutical equivalence and bioequivalence, subject to the statutory patent certifications and regulatory exclusivity framework.

The patent litigation did not itself establish final FDA approval. FDA approval would remain subject to the Paragraph IV litigation stay, any settlement terms, regulatory review and applicable exclusivity restrictions.

## How strong was Vifor's patent estate?

The Veltassa estate was commercially meaningful but exposed to standard pharmaceutical patent risks.

Strength factor	Assessment
Product-specific protection	Stronger where claims directly covered patiromer composition
Formulation protection	Dependent on claim scope and differences in the ANDA formulation
Method-of-use protection	Dependent on the proposed label and induced-infringement theory
Patent-family depth	Continuations and related patents increased the potential litigation surface
Invalidity exposure	Subject to obviousness, written-description and enablement challenges
Regulatory leverage	Orange Book listing supported the 30-month stay mechanism
Generic design-around risk	Material if Sandoz could alter excipients, particle properties or labeling

The estate's principal value was its ability to delay or negotiate generic entry. The case outcome did not produce a public merits ruling that would have materially narrowed the validity of the core patents.

## What generic entry risks existed for Veltassa?

Veltassa faced several generic-entry risks:

1. A Paragraph IV applicant could obtain a favorable ruling before patent expiration.
2. A court could find that the proposed generic did not infringe the asserted claims.
3. A generic could use a formulation design-around.
4. A section viii carve-out could remove a patented method of use from the proposed label.
5. A settlement could authorize entry before the latest patent expiration date.
6. Other ANDA applicants could file independent challenges not controlled by the Sandoz settlement.

The risk was therefore broader than the result in one case. Vifor's commercial protection depended on the full patent family, the number of competing ANDAs, settlement language and the enforceability of the listed claims.

## Which companies competed with Vifor in potassium-binding drugs?

Veltassa competed principally with AstraZeneca's Lokelma, whose active ingredient is sodium zirconium cyclosilicate. The products share the hyperkalemia market but have different active ingredients, dosing characteristics, safety considerations and patent estates.

Product	Active ingredient	Sponsor	Regulatory pathway
Veltassa	Patiromer sorbitex calcium	Vifor/Relypsa	NDA
Lokelma	Sodium zirconium cyclosilicate	AstraZeneca	NDA
Kayexalate	Sodium polystyrene sulfonate	Multiple manufacturers	Legacy product

Veltassa's patent litigation risk was therefore product-specific. A generic patiromer launch could pressure Veltassa pricing even if Lokelma remained protected by a separate patent estate.

## What revenue exposure did the litigation create?

The economic exposure was tied to Veltassa's U.S. sales, payer positioning and the timing of generic entry. A first generic launch could reduce price and market share rapidly, particularly if multiple manufacturers entered at the same time.

A settlement that delayed Sandoz entry could preserve branded revenue during the negotiated period. It would not necessarily prevent later erosion from other generic applicants. The effect on Vifor's consolidated revenue would also depend on licensing, royalty arrangements and the allocation of U.S. Veltassa economics after Vifor's acquisition of Relypsa.

## What does the case mean for generic launch timing?

The case did not establish a public court-ordered launch date. The practical launch date would depend on:

• The expiration of the applicable Veltassa patents;
• Any applicable patent-term adjustment or pediatric extension;
• The terms of the Sandoz resolution;
• FDA approval of Sandoz's ANDA;
• First-filer exclusivity held by another ANDA applicant; and
• Additional Veltassa litigation involving other generic manufacturers.

The termination of the case removed Sandoz-specific litigation from the active docket but did not eliminate the broader possibility of generic patiomer competition.

## What geographic coverage did the Vifor patent estate provide?

The case addressed U.S. rights only. The patents and FDA regulatory issues were specific to the United States. Vifor's international rights were governed by separate national or regional patent systems, regulatory approvals and licensing arrangements.

A U.S. settlement did not automatically resolve European, Canadian, Japanese or other foreign patent disputes. Generic entry outside the United States could occur on a different schedule.

## Key Takeaways

• Vifor sued Sandoz in 2020 over an ANDA for generic Veltassa.
• The dispute concerned patiromer sorbitex calcium patents, including U.S. Patent Nos. 8,663,685 and 9,199,960.
• The case was a Hatch-Waxman Paragraph IV action in the District of New Jersey.
• The litigation ended without a reported merits judgment invalidating Vifor's core Veltassa patents.
• Orange Book listing created the regulatory basis for the litigation stay but did not establish patent validity.
• The case reduced Sandoz-specific uncertainty but did not eliminate generic-entry risk from other applicants.
• The commercial outcome depended on the settlement terms, FDA approval and the remaining Veltassa patent family.

## FAQs About Vifor v. Sandoz and Veltassa Patent Litigation

What is Vifor International AG v. Sandoz Inc.?

It is a U.S. Hatch-Waxman patent case involving Sandoz's ANDA for a generic version of Veltassa, Vifor's patiromer product for hyperkalemia.

Which court handled Vifor v. Sandoz?

The case was filed in the U.S. District Court for the District of New Jersey under Case No. 3:20-cv-01649.

What is the active ingredient in Veltassa?

Veltassa contains patiromer sorbitex calcium, an oral potassium-binding polymer.

Did Sandoz win a ruling invalidating Veltassa patents?

No reported merits decision invalidating Vifor's asserted Veltassa patents resulted from the case.

Can another generic company still challenge Veltassa patents?

Yes. A separate ANDA applicant may file its own Paragraph IV certification or pursue a different invalidity, non-infringement or formulation strategy.

## References

1. U.S. District Court for the District of New Jersey. (2020). Vifor (International) AG v. Sandoz Inc., No. 3:20-cv-01649, docket materials.
2. Vifor Pharma Ltd. (2016). Annual report 2016. Vifor Pharma.
3. Drug Price Competition and Patent Term Restoration Act, 21 U.S.C. § 355(j); 35 U.S.C. § 271(e).
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
5. U.S. Food and Drug Administration. (2023). Veltassa (patiromer sorbitex calcium) prescribing information. FDA.